Literature DB >> 16854466

Transcriptional control of the C3a receptor gene in glial cells: Dependence upon AP-1 but not Ets.

Carol B Martin1, Sarah A Ingersoll, Brian K Martin.   

Abstract

The C3a anaphylatoxin has been implicated in several autoimmune states including arthritis and multiple sclerosis. The expression pattern of the C3a receptor (C3aR) is critically important in C3a biology, yet very little is known about the transcriptional control of the C3aR gene. Since C3a is hypothesized to play a role in neuroinflammation, we investigated the molecular mechanisms governing C3aR expression in astrocytes and microglia. In the current study, we demonstrate that C3aR transcription in microglia mirrors that in other macrophages, with strong transcription factor binding at the AP-1 and Ets sites. In transformed astrocytes there is evidence for AP-1 and Ets binding in the C3aR promoter region, while in primary astrocytes these sites do not apparently bind strongly to these transcription factors. Primary astrocytes lack a strong complex at the C3aR AP-1 site and reporter gene assays indicate a much smaller contribution of this site to transcriptional activity. Although EMSA analyses using astrocyte extracts show strong complexes exist at the Ets site, this sequence has a minimal activity in reporter assays. Finally, in vivo footprinting demonstrates much stronger DNA binding activity at both the AP-1 and Ets sites in microglia when compared to astrocytes. Collectively, our data demonstrate that transcriptional control of C3aR expression in astrocytes is fundamentally different than that in myeloid cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16854466     DOI: 10.1016/j.molimm.2006.04.017

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  9 in total

1.  Complement Peptide C3a Promotes Astrocyte Survival in Response to Ischemic Stress.

Authors:  Noriko Shinjyo; Yolanda de Pablo; Milos Pekny; Marcela Pekna
Journal:  Mol Neurobiol       Date:  2015-05-14       Impact factor: 5.590

2.  The complement C3a-C3aR and C5a-C5aR pathways promote viability and inflammation of human retinal pigment epithelium cells by targeting NF-κB signaling.

Authors:  Shasha Luo; Huiyan Xu; Xuechun Gong; Jinyan Shen; Xuan Chen; Zhifeng Wu
Journal:  Exp Ther Med       Date:  2022-06-07       Impact factor: 2.751

3.  A novel role of complement in retinal degeneration.

Authors:  Minzhong Yu; Weilin Zou; Neal S Peachey; Thomas M McIntyre; Jinbo Liu
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-19       Impact factor: 4.799

Review 4.  Signaling pathways regulating neuron-glia interaction and their implications in Alzheimer's disease.

Authors:  Hong Lian; Hui Zheng
Journal:  J Neurochem       Date:  2015-11-30       Impact factor: 5.372

5.  Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease.

Authors:  Hong Lian; Alexandra Litvinchuk; Angie C-A Chiang; Nadia Aithmitti; Joanna L Jankowsky; Hui Zheng
Journal:  J Neurosci       Date:  2016-01-13       Impact factor: 6.167

Review 6.  Transcriptional control of complement receptor gene expression.

Authors:  Brian K Martin
Journal:  Immunol Res       Date:  2007       Impact factor: 4.505

Review 7.  Complement system in pathogenesis of AMD: dual player in degeneration and protection of retinal tissue.

Authors:  Milosz P Kawa; Anna Machalinska; Dorota Roginska; Boguslaw Machalinski
Journal:  J Immunol Res       Date:  2014-09-04       Impact factor: 4.818

Review 8.  The role of the complement system in Multiple Sclerosis: A review.

Authors:  Nil Saez-Calveras; Olaf Stuve
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

9.  Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype.

Authors:  Konstantin Dirscherl; Marcus Karlstetter; Stefanie Ebert; Dominik Kraus; Julia Hlawatsch; Yana Walczak; Christoph Moehle; Rudolf Fuchshofer; Thomas Langmann
Journal:  J Neuroinflammation       Date:  2010-01-14       Impact factor: 8.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.